Synthetic peroxisome proliferator-activated receptor-γ agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 312-318

  Kinoshita, Hiroyuki ^a   Azma, Toshiharu ^b   Iranami, Hiroshi ^c   Nakahata, Katsutoshi ^a   Kimoto, Yoshiki ^a   Dojo, Mayuko ^a   Yuge, Osafumi ^d   Hatano, Yoshio ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b JA HIROSHIMA GENERAL HOSPITAL   (Japan)

^c JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FENOFIBRATE; GLIBENCLAMIDE; GLUCOSE; LEMAKALIM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; POTASSIUM CHANNEL; ROSIGLITAZONE; SUPEROXIDE; TIRON; TROGLITAZONE; XANTHINE OXIDASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; HYPERPOLARIZATION; MALE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASODILATATION;

ADENOSINE TRIPHOSPHATE; AGED; CROMAKALIM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNELS; PPAR GAMMA; VASCULAR DISEASES; VASODILATION;

EID: 33745243327     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.100958     Document Type: Article

References (28)

1. Azma T, Fujii K, and Yuge O (1996) Self-limiting enhancement by nitric oxide of oxygen free radical-induced endothelial cell injury: evidence against the dual action of NO as hydroxyl radical donor/scavenger. Br J Pharmacol 119:455-462.
2. 2+ channels. Br J Pharmacol 126:1462-1470.
3. Bagi Z, Koller A, and Kaley G (2004) PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol 286:H742-H748.
4. Cominacini L, Garbin U, Pastorino AM, Campagnola M, Pasini AF, Davoli A, Rigoni A, and Cascio VL (1997) Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia 40:165-172.
5. Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, and Gilkeson GS (2005) Peroxisome proliferation-activated receptor (PPAR)γ is not necessary for synthetic PPAR-γ agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther 312:69-76.
6. de la Lastra CA, Sánchez-Fidalgo S, Villegas I, and Motilva V (2004) New pharmacological perspectives and therapeutic potential of PPAR-γ agonists. Curr Pharm Des 10:3505-3524.
7. Erdös B, Simandle SA, Snipes JA, Miller AW, and Busija DW (2004) Potassium channel dysfunction in cerebral arteries of insulin-resistant rats is mediated by reactive oxygen species. Stroke 35:964-969.
8. Grundy SM and Vega GL (1987) Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 83:9-20.
9. Gutterman DD, Miura H, and Liu Y (2005) Redox modulation of vascular tone: Focus of potassium channel mechanisms of dilation. Arterioscler Thromb Vasc Biol 25:671-678.
10. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, and Hart M (2005) Peroxisome proliferators-activated receptor-γ ligands regulate endothelial membrane superoxide production. Am J Physiol 288:C899-C905.
11. 2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism 50:3-11.
12. + channels in human omental artery. Arterioscler Thromb Vasc Biol 24:2290-2295.
13. + channel-mediated vasodilation. Vasc Pharmacol 38:43-49.
14. ATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24:213-266.
15. Mayhan WG and Faraci FM (1993) Responses of cerebral arterioles in diabetic rats to activation of ATP-sensitive potassium channels. Am J Physiol 265:H152-H157.
16. Miller DB and Spence JD (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155-162.
17. Miura H, Wachtel RE, Loberiza FR Jr, Saito T, Miura M, Nicolosi AC, and Gutterman DD (2003) Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels. Circ Res 92:151-158.
18. Moriwaki Y, Yamamoto T, Suda M, Nasako Y, Takahashi S, Agbedana OE, Hada T, and Higashino K (1993) Purification and immunohistochemical tissue localization of human xanthine oxidase. Biochim Biophys Acta 1164:327-330.
19. O'Neil MJ, Smith A, Heckelman PE, Obenchain JR, Gallipeau JAR, D'Arecca MA and Budavari S eds (2001) The Merck Index, 13th ed, Merck Publishing Group, Merck & Co. Inc., Rahway, NJ.
20. Quayle JM, Nelson MT, and Standen NB (1997) ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 77:1165-1232.
21. Rangwala SM and Lazar MA (2004) Peroxisome proliferators-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 25:331-336.
22. Stumvoll M and Häring H-U (2002) Glitazones: clinical effects and molecular mechanisms. Ann Med 34:217-224.
23. Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart J-C, Brandes RP, Shah A, and Staels B (2004) Peroxisome proliferator-activated receptor α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-α activation properties. Circ Res 95:1174-1182.
24. Traber MG and Sies H (1996) Vitamin E in humans: demand and delivery. Annu Rev Nutr 16:321-347.
25. Villegas I, Martin AR, Toma W, and de la Lastra CA (2004) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor γ, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur J Pharmacol 505:195-203.
26. Wagstaff AJ and Goa KL (2002) Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837.
27. ATP channels in vascular smooth muscle. Circ Res 92:1225-1232.
28. + channel openers to cerebral arteries from diabetic rats. Circ Res 81:996-1004.